NANOVIRICIDES, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that NANOVIRICIDES, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($9.47M) | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | ($8.29M) | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | ($8.59M) | Sep 27, 2024 |
| FY2023 | Jun 30, 2022 | ($8.11M) | Oct 13, 2023 |
| FY2022 | Jun 30, 2021 | ($8.82M) | Oct 13, 2022 |
| FY2021 | Jun 30, 2020 | ($13.45M) | Oct 12, 2021 |
| FY2021 | Jun 30, 2019 | ($8.42M) | Oct 12, 2021 |
| FY2020 | Jun 30, 2018 | ($8.56M) | Oct 13, 2020 |
| FY2019 | Jun 30, 2017 | ($10.30M) | Aug 23, 2019 |
| FY2018 | Jun 30, 2016 | ($10.72M) | Oct 12, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($9.59M) | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | ($8.52M) | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | ($8.94M) | Sep 27, 2024 |
| FY2023 | Jun 30, 2022 | ($8.11M) | Oct 13, 2023 |
| FY2022 | Jun 30, 2021 | ($8.74M) | Oct 13, 2022 |
| FY2021 | Jun 30, 2020 | ($8.00M) | Oct 12, 2021 |
| FY2021 | Jun 30, 2019 | ($8.66M) | Oct 12, 2021 |
| FY2020 | Jun 30, 2018 | ($9.33M) | Oct 13, 2020 |
| FY2019 | Jun 30, 2017 | ($9.60M) | Aug 23, 2019 |
| FY2018 | Jun 30, 2016 | ($8.86M) | Oct 12, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $5.55M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $5.44M | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $6.39M | Sep 27, 2024 |
| FY2023 | Jun 30, 2022 | $5.78M | Oct 13, 2023 |
| FY2022 | Jun 30, 2021 | $6.11M | Oct 13, 2022 |
| FY2021 | Jun 30, 2020 | $4.70M | Oct 12, 2021 |
| FY2021 | Jun 30, 2019 | $5.92M | Oct 12, 2021 |
| FY2020 | Jun 30, 2018 | $5.91M | Oct 13, 2020 |
| FY2019 | Jun 30, 2017 | $6.57M | Aug 23, 2019 |
| FY2018 | Jun 30, 2016 | $5.03M | Oct 12, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($8.48M) | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | ($6.32M) | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | ($5.67M) | Sep 27, 2024 |
| FY2023 | Jun 30, 2022 | ($5.89M) | Oct 13, 2023 |
| FY2022 | Jun 30, 2021 | ($8.21M) | Oct 13, 2022 |
| FY2021 | Jun 30, 2020 | ($6.67M) | Oct 12, 2021 |
| FY2021 | Jun 30, 2019 | ($6.80M) | Oct 12, 2021 |
| FY2020 | Jun 30, 2018 | ($7.78M) | Oct 13, 2020 |
| FY2019 | Jun 30, 2017 | ($7.90M) | Aug 23, 2019 |
| FY2018 | Jun 30, 2016 | ($6.83M) | Oct 12, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $57.0K | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $156.6K | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $151.7K | Sep 27, 2024 |
| FY2023 | Jun 30, 2022 | $324.3K | Oct 13, 2023 |
| FY2022 | Jun 30, 2021 | $238.8K | Oct 13, 2022 |
| FY2021 | Jun 30, 2020 | $8.6K | Oct 12, 2021 |
| FY2021 | Jun 30, 2019 | $73.8K | Oct 12, 2021 |
| FY2020 | Jun 30, 2018 | $241.8K | Oct 13, 2020 |
| FY2019 | Jun 30, 2017 | $165.0K | Aug 23, 2019 |
| FY2018 | Jun 30, 2016 | $476.4K | Oct 12, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $8.82M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $12.82M | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $16.90M | Sep 27, 2024 |
| FY2023 | Jun 30, 2022 | $23.49M | Oct 13, 2023 |
| FY2022 | Jun 30, 2021 | $30.26M | Oct 13, 2022 |
| FY2021 | Jun 30, 2020 | $23.91M | Oct 12, 2021 |
| FY2020 | Jun 30, 2019 | $13.45M | Oct 13, 2020 |
| FY2019 | Jun 30, 2018 | $18.55M | Aug 23, 2019 |
| FY2018 | Jun 30, 2017 | $27.00M | Oct 12, 2018 |
| FY2017 | Jun 30, 2016 | $36.63M | Sep 28, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $1.30M | Sep 29, 2025 |
| FY2024 | Jun 30, 2024 | $1.36M | Sep 27, 2024 |
| FY2024 | Jun 30, 2023 | $2.03M | Sep 27, 2024 |
| FY2023 | Jun 30, 2022 | $412.8K | Oct 13, 2023 |
| FY2018 | Jun 30, 2018 | $881.9K | Oct 12, 2018 |
| FY2018 | Jun 30, 2017 | $6.68M | Oct 12, 2018 |
| FY2017 | Jun 30, 2016 | $13.59M | Sep 28, 2017 |
| FY2016 | Jun 30, 2015 | $12.40M | Sep 16, 2016 |
| FY2015 | Jun 30, 2014 | $20.49M | Sep 14, 2015 |
| FY2014 | Jun 30, 2013 | $8.40M | Feb 23, 2015 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $7.52M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $11.46M | Sep 29, 2025 |
| FY2025 | Jun 30, 2023 | $14.87M | Sep 29, 2025 |
| FY2024 | Jun 30, 2022 | $23.08M | Sep 27, 2024 |
| FY2023 | Jun 30, 2021 | $29.91M | Oct 13, 2023 |
| FY2022 | Jun 30, 2020 | $21.76M | Oct 13, 2022 |
| FY2021 | Jun 30, 2019 | $10.60M | Oct 12, 2021 |
| FY2021 | Jun 30, 2018 | $17.66M | Oct 12, 2021 |
| FY2020 | Jun 30, 2017 | $20.32M | Oct 13, 2020 |
| FY2019 | Jun 30, 2016 | $23.05M | Aug 23, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($148.84M) | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | ($139.37M) | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | ($131.08M) | Sep 27, 2024 |
| FY2023 | Jun 30, 2022 | ($122.49M) | Oct 13, 2023 |
| FY2022 | Jun 30, 2021 | ($114.39M) | Oct 13, 2022 |
| FY2021 | Jun 30, 2020 | ($105.56M) | Oct 12, 2021 |
| FY2020 | Jun 30, 2019 | ($92.12M) | Oct 13, 2020 |
| FY2019 | Jun 30, 2018 | ($83.69M) | Aug 23, 2019 |
| FY2018 | Jun 30, 2017 | ($75.13M) | Oct 12, 2018 |
| FY2017 | Jun 30, 2016 | ($64.82M) | Sep 28, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $1.56M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $4.80M | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $8.15M | Sep 27, 2024 |
| FY2023 | Jun 30, 2022 | $14.07M | Oct 13, 2023 |
| FY2022 | Jun 30, 2021 | $20.52M | Oct 13, 2022 |
| FY2021 | Jun 30, 2020 | $13.71M | Oct 12, 2021 |
| FY2020 | Jun 30, 2019 | $2.56M | Oct 13, 2020 |
| FY2019 | Jun 30, 2018 | $7.08M | Aug 23, 2019 |
| FY2018 | Jun 30, 2017 | $15.10M | Oct 12, 2018 |
| FY2018 | Jun 30, 2016 | $24.16M | Oct 12, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 0 | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | 0 | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Sep 27, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Oct 13, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Oct 13, 2022 |
| FY2018 | Jun 30, 2018 | 0 | Oct 12, 2018 |
| FY2018 | Jun 30, 2017 | 0 | Oct 12, 2018 |
| FY2018 | Jun 30, 2016 | 0 | Oct 12, 2018 |
| FY2017 | Jun 30, 2015 | 0 | Sep 28, 2017 |
| FY2016 | Jun 30, 2014 | 0 | Sep 16, 2016 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 0 | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | 0 | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Sep 27, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Oct 13, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Oct 13, 2022 |
| FY2018 | Jun 30, 2018 | 0 | Oct 12, 2018 |
| FY2018 | Jun 30, 2017 | 0 | Oct 12, 2018 |
| FY2018 | Jun 30, 2016 | 0 | Oct 12, 2018 |
| FY2017 | Jun 30, 2015 | 0 | Sep 28, 2017 |
| FY2016 | Jun 30, 2014 | 0 | Sep 16, 2016 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 16.61M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | 13.14M | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | 11.70M | Sep 27, 2024 |
| FY2023 | Jun 30, 2022 | 11.59M | Oct 13, 2023 |
| FY2022 | Jun 30, 2021 | 11.52M | Oct 13, 2022 |
| FY2021 | Jun 30, 2020 | 9.08M | Oct 12, 2021 |
| FY2020 | Jun 30, 2019 | 3.84M | Oct 13, 2020 |
| FY2019 | Jun 30, 2018 | 69.17M | Aug 23, 2019 |
| FY2018 | Jun 30, 2017 | 63.31M | Oct 12, 2018 |
| FY2017 | Jun 30, 2016 | 58.18M | Sep 28, 2017 |